PER-099-03Completed未知
RANDOMIZED STUDY OF PHASE II / III OF PACLITAXEL + CARBOPLATINO WITH OR WITHOUT BEVACIZUMAB IN PATIENTS WITH ADVANCED PULMON CANCER OR METASTASIC NO SCAMOSO NSCLC.
EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG),0 sites0 target enrollmentStarted: February 27, 2004Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •not contemplated
Exclusion Criteria
- •not contemplated
Investigators
Similar Trials
Active, not recruiting
Phase 1
Clinical study to assess safety and efficacy of Paclitaxel + GDC-0941 versus Paclitaxel + Placebo in metastatic breast cancer patients.MedDRA version: 18.0 Level: LLT Classification code 10027475 Term: Metastatic breast cancer System Organ Class: 100000004864Metastatic Breast CancerEUCTR2012-003262-41-GBGenentech, Inc.179
Active, not recruiting
Phase 1
Clinical study to assess safety and efficacy of Paclitaxel + GDC-0941 versus Paclitaxel + Placebo in metastatic breast cancer patients.MedDRA version: 15.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864Metastatic Breast CancerEUCTR2012-003262-41-ESGenentech, Inc.180
Active, not recruiting
Phase 1
Clinical study to assess safety and efficacy of Paclitaxel + GDC-0941 versus Paclitaxel + Placebo in metastatic breast cancer patients.Metastatic Breast CancerEUCTR2012-003262-41-BEGenentech, Inc.180
Active, not recruiting
Phase 1
Clinical study to assess safety and efficacy of Paclitaxel + GDC-0941 versus Paclitaxel + Placebo in metastatic breast cancer patients.MedDRA version: 19.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864Metastatic Breast CancerEUCTR2012-003262-41-CZGenentech, Inc.180
Active, not recruiting
Phase 1
Clinical study to assess safety and efficacy of Paclitaxel + GDC-0941 versus Paclitaxel + Placebo in metastatic breast cancer patients.Metastatic Breast CancerEUCTR2012-003262-41-ATGenentech, Inc.180